Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OMALIZUMAB Cause Obstructive airways disorder? 1,670 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 1,670 reports of Obstructive airways disorder have been filed in association with OMALIZUMAB (Omalizumab-igec). This represents 2.6% of all adverse event reports for OMALIZUMAB.

1,670
Reports of Obstructive airways disorder with OMALIZUMAB
2.6%
of all OMALIZUMAB reports
32
Deaths
971
Hospitalizations

How Dangerous Is Obstructive airways disorder From OMALIZUMAB?

Of the 1,670 reports, 32 (1.9%) resulted in death, 971 (58.1%) required hospitalization, and 113 (6.8%) were considered life-threatening.

Is Obstructive airways disorder Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OMALIZUMAB. However, 1,670 reports have been filed with the FAERS database.

What Other Side Effects Does OMALIZUMAB Cause?

No adverse event (9,736) Asthma (9,354) Urticaria (9,231) Off label use (9,199) Dyspnoea (8,323) Drug ineffective (6,747) Cough (5,926) Pruritus (5,224) Fatigue (5,053) Malaise (4,820)

What Other Drugs Cause Obstructive airways disorder?

ALBUTEROL (4,195) TIOTROPIUM (2,634) PREDNISONE (2,480) BUDESONIDE\FORMOTEROL (2,210) MONTELUKAST (2,073) MEPOLIZUMAB (1,883) CICLESONIDE (1,403) FLUTICASONE\SALMETEROL (1,253) BUDESONIDE (1,214) IPRATROPIUM (1,171)

Which OMALIZUMAB Alternatives Have Lower Obstructive airways disorder Risk?

OMALIZUMAB vs OMAVELOXOLONE OMALIZUMAB vs OMBITASVIR OMALIZUMAB vs OMBITASVIR\PARITAPREVIR\RITONAVIR OMALIZUMAB vs OMEGA-3-ACID ETHYL ESTERS OMALIZUMAB vs OMEGA-3-CARBOXYLIC ACIDS

Related Pages

OMALIZUMAB Full Profile All Obstructive airways disorder Reports All Drugs Causing Obstructive airways disorder OMALIZUMAB Demographics